Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.2% - Should You Sell?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s share price fell 5.2% on Tuesday . The company traded as low as $7.70 and last traded at $7.84. 6,611,662 shares changed hands during mid-day trading, an increase of 4% from the average session volume of 6,380,387 shares. The stock had previously closed at $8.27.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RXRX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Jefferies Financial Group cut their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research note on Tuesday, September 3rd. Finally, Leerink Partners lowered their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Recursion Pharmaceuticals presently has an average rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Down 11.2 %

The firm's 50-day simple moving average is $6.64 and its 200 day simple moving average is $7.30. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a market cap of $2.10 billion, a P/E ratio of -4.97 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company posted ($0.43) EPS. The company's revenue for the quarter was up 147.6% compared to the same quarter last year. On average, research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other news, CEO Christopher Gibson sold 20,000 shares of the firm's stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $6.16, for a total transaction of $123,200.00. Following the sale, the chief executive officer now owns 762,656 shares of the company's stock, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction that occurred on Tuesday, September 17th. The shares were sold at an average price of $6.84, for a total value of $78,297.48. Following the completion of the transaction, the director now owns 7,109,875 shares of the company's stock, valued at $48,631,545. This represents a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 119,235 shares of company stock worth $802,988 in the last ninety days. Company insiders own 15.75% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its holdings in shares of Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company's stock worth $12,789,000 after acquiring an additional 288,926 shares during the period. FMR LLC lifted its holdings in shares of Recursion Pharmaceuticals by 2.1% in the third quarter. FMR LLC now owns 8,363,530 shares of the company's stock valued at $55,116,000 after purchasing an additional 170,810 shares in the last quarter. Perceptive Advisors LLC acquired a new position in shares of Recursion Pharmaceuticals during the second quarter worth about $5,769,000. Pier 88 Investment Partners LLC grew its holdings in shares of Recursion Pharmaceuticals by 442.1% during the third quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company's stock worth $882,000 after buying an additional 109,210 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its position in Recursion Pharmaceuticals by 6,439.6% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company's stock valued at $1,274,000 after buying an additional 167,302 shares during the last quarter. Institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.